Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Zinc Transporter 8 (ZnT8) Antibody

Test code(s) 93022

This test is mainly used to assist in the diagnosis of type 1 diabetes mellitus. For this purpose, it can be used alone or in combination with other antibody tests such as the glutamic acid decarboxylase-65 (GAD-65), insulinoma antigen-2 (IA-2), and insulin antibody tests.

ZnT8 antibody testing can be considered for:

  • Individuals with diabetes of uncertain etiology
    • Young person with atypical diabetes
    • Person with ketosis-prone diabetes that is not clearly type 1
    • Person suspected of having maturity-onset diabetes of the young (MODY)
    • Woman with gestational diabetes (help clarify risk of future diabetes)
  • Obese individuals with acute-onset diabetes with ketoacidosis
  • Lean individuals with nonketotic diabetes
  • Individuals at high risk of developing type 1 diabetes (eg, those with a first-degree relative with type 1 diabetes) in context of a clinical research study1

65 to 80% of children with recently diagnosed type 1 diabetes2,3 and 20% to 40% of adults with type 1 diabetes3,4 have antibodies to ZnT8.

The ZnT8 antibody can add 3% to 4% to the antibody sensitivity for type 1 diabetes. This is because ZnT8 antibody is positive in 3% to 4% of patients who are negative for GAD-65, IA-2, and insulin antibodies.2,5,6 Use of these 4 antibodies results in 93% to 98% sensitivity.2,5,6

ZnT8 antibody testing may help to assess the risk of type 1 diabetes. Achenbach et al found that almost half of children with ZnT8 antibody developed type 1 diabetes within 5 years.7 Moreover, since risk of type 1 diabetes increases with the number of antibodies, a positive ZnT8 antibody test can reclassify individuals into a higher risk category.

ZnT8 antibodies can be detected as early as 9 months of age but are more common after 2 years.2,7 Antibody titers decrease over the course of the disease, and patients who are initially ZnT8 antibody-positive may later become antibody- negative.3,5,8

 

References

  1. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(suppl 1):S8-S16.
  2. Andersson C, Vaziri-Sani F, Delli AJ, et al. Triple specificity of ZnT8 autoantibodies in relationship to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes. 2013;14:97-105.
  3. Vaziri-Sani F, Oak S, Radtke J, et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity. 2010;43:598-606.
  4. Kawasaki E, Nakamura K, Kuriya G, et al. Differences in humoral autoreactivity to zinc transporter 8 between childhood- and adult-onset type 1 diabetes in Japanese patients. Clin Immunol. 2011;138:146-153.
  5. Petruzelkova L, Ananieva-Jordanova R, Vcelakova J, et al. The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of type 1 diabetes mellitus. Diabet Med. 2014;31:165-171.
  6. Wenzlau JM, Moua O, Sarkar SA, et al. SLC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann NY Acad Sci. 2008;1150:256-259.
  7. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia. 2009;52:1881-1888.
  8. Wenzlau JM, Walter M, Gardner TJ, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab. 2010;95:4712-4719.

 

This FAQ is provided for informational purposes only and is not intended as medical advice. A clinician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

Document FAQS.168 Version: 0
Effective 06/24/2015 to present

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.